DK1471057T3 - Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 - Google Patents

Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2

Info

Publication number
DK1471057T3
DK1471057T3 DK03009384T DK03009384T DK1471057T3 DK 1471057 T3 DK1471057 T3 DK 1471057T3 DK 03009384 T DK03009384 T DK 03009384T DK 03009384 T DK03009384 T DK 03009384T DK 1471057 T3 DK1471057 T3 DK 1471057T3
Authority
DK
Denmark
Prior art keywords
crth2
treatment
acid derivatives
diseases mediated
derivatives suitable
Prior art date
Application number
DK03009384T
Other languages
English (en)
Inventor
Ly Tai Wie
Yuji Koriyama
Takashi Yoshino
Hiroki Sato
Kazuho Tanaka
Hiromi Sugimoto
Yoshihisa Manabe
Kevin Bacon
Klaus Urbahns
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1471057T3 publication Critical patent/DK1471057T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
DK03009384T 2003-04-25 2003-04-25 Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2 DK1471057T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03009384A EP1471057B1 (en) 2003-04-25 2003-04-25 Pyrimidinylacetic acid derivatives useful for the treatment of diseases mediated by CRTH2

Publications (1)

Publication Number Publication Date
DK1471057T3 true DK1471057T3 (da) 2006-05-15

Family

ID=32946880

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03009384T DK1471057T3 (da) 2003-04-25 2003-04-25 Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
DK04727274.5T DK1633726T3 (da) 2003-04-25 2004-04-14 Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK04727274.5T DK1633726T3 (da) 2003-04-25 2004-04-14 Pyrimidinderivater, der er egnede til behandling af CRTH2-formidlede sygdomme

Country Status (33)

Country Link
US (2) US7812160B2 (da)
EP (2) EP1471057B1 (da)
JP (2) JP4671955B2 (da)
KR (1) KR101110491B1 (da)
CN (2) CN101914065A (da)
AR (1) AR043885A1 (da)
AT (2) ATE316077T1 (da)
AU (1) AU2004233966B2 (da)
BR (1) BRPI0409733A (da)
CA (1) CA2523439C (da)
CL (1) CL43596B (da)
CY (1) CY1111295T1 (da)
DE (2) DE60303238T2 (da)
DK (2) DK1471057T3 (da)
DO (1) DOP2004000875A (da)
ES (2) ES2257616T3 (da)
GT (1) GT200400079A (da)
HK (1) HK1095320A1 (da)
HN (1) HN2004000129A (da)
IL (1) IL171566A (da)
MX (1) MXPA05011399A (da)
MY (1) MY147984A (da)
NO (1) NO20055588L (da)
NZ (1) NZ543693A (da)
PE (1) PE20050143A1 (da)
PL (1) PL1633726T3 (da)
PT (2) PT1471057E (da)
RU (1) RU2361865C2 (da)
SI (1) SI1633726T1 (da)
TW (1) TWI353980B (da)
UY (1) UY28286A1 (da)
WO (1) WO2004096777A1 (da)
ZA (1) ZA200508722B (da)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
LT2805728T (lt) * 2003-12-23 2020-05-25 Genentech, Inc. Nauji anti-il 13 antikūnai ir jų naudojimai
DK1718649T3 (da) 2004-01-31 2009-08-24 Actimis Pharmaceuticals Inc Imidazo[1,2-c]pyrimidinyleddikesyrederivater
CN1930162B (zh) 2004-03-11 2010-06-16 埃科特莱茵药品有限公司 四氢吡啶并吲哚衍生物
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
DK1817282T3 (da) 2004-11-23 2011-10-10 Astrazeneca Ab Til behandling af respiratoriske sygdomme egnede phenoxy derivater
MX2007012937A (es) 2005-04-21 2008-03-26 Serono Lab Pirazina-sulfonamidas 2,3-sustituidas.
US8236963B2 (en) 2005-05-24 2012-08-07 Merck Serono Sa Tricyclic spiro derivatives as CRTH2 modulators
PE20070589A1 (es) * 2005-10-04 2007-06-22 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
WO2007039736A1 (en) * 2005-10-06 2007-04-12 Astrazeneca Ab Novel compounds
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
WO2007062677A1 (en) * 2005-11-30 2007-06-07 7Tm Pharma A/S Thiazolyl- and pyrimidinyl-acetic acids and their use as crth2 receptor ligands
JP2009539880A (ja) * 2006-06-09 2009-11-19 アイコス コーポレイション Ｄｐ−２アンタゴニストとしての置換フェニル酢酸
EP2132196A1 (en) * 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
CN102898381A (zh) 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
RU2468012C2 (ru) * 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
NZ584352A (en) * 2007-09-25 2012-03-30 Actimis Pharmaceuticals Inc Alkylthio pyrimidines as CRTH2 antagonists
RU2491279C2 (ru) * 2007-09-25 2013-08-27 Актимис Фармасьютикалз, Инк. 2-s-бензилзамещенные пиримидины в качестве антагонистов crth2
US8067445B2 (en) 2008-02-01 2011-11-29 Panmira Pharmaceuticals, Llc N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
EP2257536A4 (en) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc CYCLIC DIARYL ETHERS AS ANTAGONISTS OF PROSTAGLANDIN D2 RECEPTORS
US8497381B2 (en) 2008-02-25 2013-07-30 Panmira Pharmaceuticals, Llc Antagonists of prostaglandin D2 receptors
EP2268611A2 (en) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
US20110144160A1 (en) 2008-07-03 2011-06-16 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
WO2010027448A1 (en) * 2008-09-02 2010-03-11 Actimis Pharmaceuticals Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as crth2 antagonists
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
WO2010042652A2 (en) 2008-10-08 2010-04-15 Amira Pharmaceuticals, Inc. Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
BRPI0923592A2 (pt) * 2008-12-25 2016-01-26 Taisho Pharmaceutical Co Ltd composto
EP2393492A1 (en) * 2009-02-09 2011-12-14 Boehringer Ingelheim International GmbH New pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
EP2396295A1 (en) 2009-02-12 2011-12-21 Merck Serono S.A. Phenoxy acetic acid derivatives
WO2010094643A1 (en) * 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
GB0908394D0 (en) 2009-05-15 2009-06-24 Univ Leuven Kath Novel viral replication inhibitors
JP2013500978A (ja) 2009-07-31 2013-01-10 パンミラ ファーマシューティカルズ，エルエルシー． Ｄｐ２受容体アンタゴニストの眼の医薬組成物
GB0913636D0 (en) * 2009-08-05 2009-09-16 Univ Leuven Kath Novel viral replication inhibitors
US8815917B2 (en) 2009-08-05 2014-08-26 Panmira Pharmaceuticals, Llc DP2 antagonist and uses thereof
BR112012012384A2 (pt) * 2009-11-24 2016-03-22 Boehringer Ingelheim Int processo para preparar um polímero do sal de colina de [4,6-bi(dimetilamino--2-(4-{[4-(trifluorometil)-benzoil]amino}benzil)pirimidin-5-il}
MX2012007927A (es) 2010-01-06 2012-08-15 Panmira Pharmaceuticals Llc Antagonistas de dp2 y usos del mismo.
KR101906791B1 (ko) 2010-01-27 2018-10-11 베링거 인겔하임 인터내셔날 게엠베하 Ｃｒｔｈ２ 길항제로서의 피라졸 화합물
WO2011162274A1 (ja) 2010-06-23 2011-12-29 大正製薬株式会社 イソキノリン誘導体
JP5800898B2 (ja) 2010-07-05 2015-10-28 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ １−フェニル−置換ヘテロシクリル誘導体及びプロスタグランジンｄ２受容体調節剤としてのそれらの使用
WO2012013567A1 (en) 2010-07-28 2012-02-02 Boehringer Ingelheim International Gmbh Pharmaceutical composition for treatment of respiratory and inflammatory diseases
JP2013535456A (ja) 2010-07-28 2013-09-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 呼吸器系及び炎症性疾患の治療用医薬組成物
CN102803407B (zh) 2010-10-20 2016-11-16 威士伯采购公司 对包括铁素体不锈钢在内的宽范围的经涂布和未经涂布的基材具有改善粘附性的水基涂料体系
CA2817165A1 (en) 2010-11-15 2012-05-24 Patrick Chaltin Novel antiviral compounds
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
TWI527809B (zh) 2011-01-24 2016-04-01 百靈佳殷格翰國際股份有限公司 作為ｃｒｔｈ２拮抗劑之吡唑化合物
EP2688882B1 (en) 2011-03-25 2015-05-13 Boehringer Ingelheim International GmbH Pyrazole compounds as crth2 antagonists
EP2709988B1 (en) 2011-05-16 2017-07-05 Boehringer Ingelheim International Gmbh Process for preparing [4,6-bis-dimethylamino-2-[4-(4-trifluoromethylbenzoyl-amino)benzyl]pyrimidin-5-yl]acetic acid
US20140328861A1 (en) 2011-12-16 2014-11-06 Atopix Therapeutics Limited Combination of CRTH2 Antagonist and a Proton Pump Inhibitor for the Treatment of Eosinophilic Esophagitis
EP2794563B1 (en) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2885307A1 (en) 2012-07-05 2015-06-24 Actelion Pharmaceuticals Ltd. 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
WO2014079806A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrimidine compounds for treating hairloss
TWI695831B (zh) 2014-09-13 2020-06-11 香港商南北兄弟藥業投資有限公司 Ｃｒｔｈ２拮抗劑化合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9125842D0 (en) * 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
US6326368B1 (en) * 1996-03-27 2001-12-04 Dupont Pharmaceuticals Company Aryloxy- and arylthiosubstituted pyrimidines and triazines and derivatives thereof
JP2001302667A (ja) 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
CA2408727A1 (en) * 2000-05-22 2001-11-29 Leo Pharma A/S Benzophenones as inhibitors of il-1.beta. and tnf-.alpha.
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
EP1413306A1 (en) * 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydroquinoline derivatives as CRTH2 antagonists
EP1585511B1 (en) 2002-12-20 2013-01-23 Amgen Inc. Asthma and allergic inflammation modulators
PT1471057E (pt) 2003-04-25 2006-05-31 Actimis Pharmaceuticals Inc Derivados de acido pirimidinilacetico uteis para o tratamento de doencas mediadas por crth2
RU2468012C2 (ru) 2007-06-21 2012-11-27 Актимис Фармасьютикалз, Инк. Частицы антагониста crth2
CN102898381A (zh) 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐

Also Published As

Publication number Publication date
ATE494279T1 (de) 2011-01-15
MXPA05011399A (es) 2006-05-31
NO20055588L (no) 2006-01-24
ZA200508722B (en) 2006-12-27
BRPI0409733A (pt) 2006-05-09
CN1809539A (zh) 2006-07-26
TW200505873A (en) 2005-02-16
SI1633726T1 (sl) 2011-04-29
UY28286A1 (es) 2004-11-30
PT1633726E (pt) 2011-02-22
HN2004000129A (es) 2009-05-14
DE60303238T2 (de) 2006-09-14
AU2004233966B2 (en) 2010-11-11
IL171566A (en) 2011-03-31
WO2004096777A1 (en) 2004-11-11
PE20050143A1 (es) 2005-04-01
EP1633726B1 (en) 2011-01-05
ATE316077T1 (de) 2006-02-15
EP1633726A1 (en) 2006-03-15
CY1111295T1 (el) 2015-08-05
HK1095320A1 (en) 2007-05-04
RU2361865C2 (ru) 2009-07-20
AU2004233966A1 (en) 2004-11-11
JP2006524645A (ja) 2006-11-02
CA2523439C (en) 2012-06-19
AR043885A1 (es) 2005-08-17
DE60303238D1 (de) 2006-04-06
JP2011068657A (ja) 2011-04-07
PT1471057E (pt) 2006-05-31
RU2005136655A (ru) 2006-06-10
KR101110491B1 (ko) 2012-01-31
DOP2004000875A (es) 2004-10-31
ES2358424T3 (es) 2011-05-10
TWI353980B (en) 2011-12-11
JP4671955B2 (ja) 2011-04-20
PL1633726T3 (pl) 2011-06-30
CL43596B (es) 2005-03-18
GT200400079A (es) 2004-11-30
US7812160B2 (en) 2010-10-12
DK1633726T3 (da) 2011-03-28
DE602004030907D1 (de) 2011-02-17
NZ543693A (en) 2009-05-31
US20070129355A1 (en) 2007-06-07
MY147984A (en) 2013-02-28
NO20055588D0 (no) 2005-11-25
US20100322980A1 (en) 2010-12-23
EP1471057A1 (en) 2004-10-27
CA2523439A1 (en) 2004-11-11
KR20060089622A (ko) 2006-08-09
CN1809539B (zh) 2012-05-09
JP5161290B2 (ja) 2013-03-13
CN101914065A (zh) 2010-12-15
ES2257616T3 (es) 2006-08-01
US7960393B2 (en) 2011-06-14
EP1471057B1 (en) 2006-01-18

Similar Documents

Publication Publication Date Title
DK1471057T3 (da) Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
DK1656347T3 (da) Substituerede indolderivater til farmaceutisk sammensætning til behandling af luftvejssygdomme
DK1708992T3 (da) Sulfonamidderivater til behandling af sygdomme
DK1716162T3 (da) Phosphonater, amidomonophosphonater, amidobisphosphonater til behandling af virussygdomme
DK1701941T3 (da) Forbindelser til behandling af sygdomme med celleproliferation
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1708991T3 (da) Sulfonamid derivater til behandling af sygdomme
DK1830843T3 (da) Indolidon-derivater til behandling eller forebyggelse af fibrotiske sygdomme
DK1778673T3 (da) Nye hydantoin-derivater til behandling af obstruktive luftvejssygdomme
DK1478358T3 (da) Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
DK1948615T3 (da) Til behandling af gynækologiske sygdomme egnede pyrazolderivater
DE502004008604D1 (de) Pyrrolopyridin-substitutierte benzol-derivate zur behandlung kardiovaskulärer erkrankungen
DK1556342T3 (da) Phenethanolaminderivat til behandling af respiratoriske sygdomme
DK1656346T3 (da) 1,2,3,4-tetrasubstituerede indol til behandling af luftvejssygdomme
DK1474416T3 (da) Dihydrobenzodiazepin-2-on-derivater til behandlingen af neurologiske lidelser
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
DK2422786T3 (da) Nye lægemiddelkombinationer til behandling af luftvejssygdomme
DK1940409T3 (da) Nye lægemiddelkombinationer til behandling af åndedrætssygdomme
DK1685125T3 (da) Pyrrolderivater der er nyttige til behandlingen af proliferative sygdomme
DK1856063T3 (da) 5-phenyl-pentansyrederivater som matrix- metalloproteinaseinhibitorer til behandlingen af astma og andre sygdomme
DK1881830T3 (da) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinolin-derivater til behandling af infertilitet
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme